#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14188	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2169	649.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1552	1552	C	843	C	778	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25302	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3589	703.0	0	.	n	.	0	T695C	SNP	695	695	T	1018	1018	C	865	C	817	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25302	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3589	703.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2294	2294	C	809	C	762	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25302	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3589	703.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2920	2920	T	699	T,C	497,175	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25302	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3589	703.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2368	2368	A	808	A	764	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2056	folP	852	852	100.0	folP.l15.c4.ctg.1	1485	137.6	1	SNP	p	R228S	1	.	.	682	684	AGC	994	996	AGC	211;213;212	A;G;C	194;196;193	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5562	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3402	162.8	1	SNP	p	S91F	0	.	.	271	273	TCC	661	663	TCC	213;215;214	T;C;C	200;204;202	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5562	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3402	162.8	1	SNP	p	D95G	0	.	.	283	285	GAC	673	675	GAC	214;215;213	G;A;C	202;202;201	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5562	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3402	162.8	1	SNP	p	D95N	0	.	.	283	285	GAC	673	675	GAC	214;215;213	G;A;C	202;202;201	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_W_01449	mtrR.WHO_W_01449	1	1	27	1662	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1456	113.8	1	SNP	p	G45D	1	.	.	133	135	GAC	545	547	GAC	222;223;222	G;A;C	207;206;209	mtrR.WHO_W_01449:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	882	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c30.ctg.1	1029	85.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5042	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2959	169.5	1	SNP	p	D86N	0	.	.	256	258	GAC	489	491	GAC	194;194;194	G;A;C	184;182;186	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5042	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2959	169.5	1	SNP	p	S87R	0	.	.	259	261	AGT	492	494	AGT	197;196;197	A;G;T	189;189;189	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5042	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2959	169.5	1	SNP	p	S87I	0	.	.	259	261	AGT	492	494	AGT	197;196;197	A;G;T	189;189;189	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5042	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2959	169.5	1	SNP	p	S87W	0	.	.	259	261	AGT	492	494	AGT	197;196;197	A;G;T	189;189;189	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5042	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2959	169.5	1	SNP	p	S88P	0	.	.	262	264	TCC	495	497	TCC	197;199;199	T;C;C	189;192;192	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4350	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2710	160.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1542	1544	GGC	223;223;220	G;G;C,T	208;206;199,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	A311V	0	.	.	931	933	GCA	1274	1276	GCA	201;203;201	G,A;C;A	190,1;195;195	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	I312M	0	.	.	934	936	ATC	1277	1279	ATC	201;200;200	A;T;C	195;194;193	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	V316T	0	.	.	946	948	GTG	1289	1291	GTG	206;203;206	G;T;G	200;193;199	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	V316P	0	.	.	946	948	GTG	1289	1291	GTG	206;203;206	G;T;G	200;193;199	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1793	1795	ACC	188;188;188	A;C;C	176;178;179	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1847	1849	GCG	183;181;181	G,A;C,G;G	153,1;140,2;148	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1847	1849	GCG	183;181;181	G,A;C,G;G	153,1;140,2;148	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1970	1972	GGC	153;151;149	G;G;C	143;139;137	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1979	1981	GGC	147;145;144	G;G;C	134;132;132	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2413	151.0	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1997	1999	CCG	118;122;124	C,CGG;C;G	95,1;101;99	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5248	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3016	173.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2448	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1839	132.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	533	533	C	190	C	176	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	379	381	GGA	195;191;193	G;G;A	192;188;188	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	V75I	NONSYN	223	225	GTT	460	462	ATT	177;178;178	A;T;T	168;168;169	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	T89S	NONSYN	265	267	ACC	502	504	AGC	186;184;186	A;G;C	177;175;175	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	V98I	NONSYN	292	294	GTC	529	531	ATC	188;188;189	A;T,A;C	181;180,1;183	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	.	MULTIPLE	358	359	AA	594	595	CG	190;189	CGG,CG;G,A	181,1;177,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	.	MULTIPLE	361	362	GA	597	599	CAG	196;194;196	C;A;G,A	187;184;184,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	N122K	NONSYN	364	366	AAC	601	603	AAA	197;197;198	A;A;A,C	190;191;192,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	K143E	NONSYN	427	429	AAA	664	666	GAA	187;186;188	G,A;A;A	178,1;178;178	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	V151A	NONSYN	451	453	GTA	688	690	GCA	186;186;185	G;C;A	171;173;170	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	T213S	NONSYN	637	639	ACA	874	876	TCA	166;166;166	T;C;A	162;162;163	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	994	996	CAA	183;183;182	C;A;A	179;179;178	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	.	INDELS	760	762	ACA	998	1002	ATCAA	180;182;183;185;185	A;T;C;A;A	175;176;179;181;182	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	.	INDELS	763	764	TG	1005	1007	AGT	185;187;184	A;G;T	182;184;181	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1012	1014	GAT	188;187;186	G;A,C;T	182;181,1;180	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1120	1122	AGT	221;222;224	A;G;T	207;208;211	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1126	1128	GAC	226;223;223	G;A;C	215;213;213	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1129	1131	TAC	221;224;221	T;A;C	211;214;212	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	1	SNP	p	G120K	1	.	.	358	360	AAG	594	596	CGG	190;189;191	CGG,CG;G,A;G	181,1;177,1;179	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	1	SNP	p	A121D	1	.	.	361	363	GAC	597	600	CGC	196;196;196	C;G,A;C	187;184,1;189	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2412	porB1b	1041	1041	97.23	porB1b.l15.c17.ctg.1	1428	168.1	1	SNP	p	D121N	0	.	.	361	363	GAC	597	600	CGC	196;196;196	C;G,A;C	187;184,1;189	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9242	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4825	190.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2036	2038	AAT	201;201;202	A;A;T	194;194;192	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1018	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1187	85.5	1	SNP	p	V57M	1	.	.	169	171	ATG	688	690	ATG	211;209;208	A;T;G	202;200;201	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
